NYSE:NGVT - Ingevity Stock Price, Price Target & More

Ingevity trades on the New York Stock Exchange (NYSE) under the ticker symbol "NGVT."

Ingevity (NYSE:NGVT) released its quarterly earnings results on Wednesday, May, 2nd. The company reported $0.79 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.63 by $0.16. The business earned $235.20 million during the quarter, compared to analyst estimates of $231.76 million. Ingevity had a return on equity of 48.09% and a net margin of 13.96%. Ingevity's revenue for the quarter was up 7.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.49 earnings per share. View Ingevity's Earnings History.

Ingevity is scheduled to release their next quarterly earnings announcement on Wednesday, August, 1st 2018. View Earnings Estimates for Ingevity.

8 Wall Street analysts have issued 12-month price objectives for Ingevity's shares. Their forecasts range from $67.00 to $92.00. On average, they anticipate Ingevity's stock price to reach $86.3750 in the next twelve months. View Analyst Ratings for Ingevity.

Some companies that are related to Ingevity include FMC (FMC), The Chemours (CC), Johnson Matthey (JMPLY), Huntsman (HUN), Olin (OLN), W. R. Grace and (GRA), Ashland (ASH), Univar (UNVR), Balchem (BCPC), GCP Applied Technologies (GCP), PQ Group (PQG), Innospec (IOSP), KMG Chemicals (KMG), Innophos (IPHS) and OCI Partners (OCIP).

Headlines about NGVT stock have trended somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies positive and negative press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Ingevity earned a coverage optimism score of 0.21 on Accern's scale. They also assigned news articles about the company an impact score of 44.52 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

Ingevity's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (13.20%), Franklin Resources Inc. (4.09%), Chilton Investment Co. LLC (2.27%), Silvercrest Asset Management Group LLC (2.22%), Massachusetts Financial Services Co. MA (2.05%) and Loomis Sayles & Co. L P (1.78%). View Institutional Ownership Trends for Ingevity.

NGVT stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Royal Bank of Canada, Millennium Management LLC, Silvercrest Asset Management Group LLC, Wells Fargo & Company MN, Loomis Sayles & Co. L P, Chilton Investment Co. LLC and Mesirow Financial Investment Management Equity Management. View Insider Buying and Selling for Ingevity.

NGVT stock was purchased by a variety of institutional investors in the last quarter, including Summit Trail Advisors LLC, Palisade Capital Management LLC NJ, BlackRock Inc., Prudential Financial Inc., Dimensional Fund Advisors LP, OppenheimerFunds Inc., Natixis Advisors L.P. and Old Mutual Global Investors UK Ltd.. View Insider Buying and Selling for Ingevity.

Shares of NGVT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of NGVT stock can currently be purchased for approximately $79.63.

Ingevity has a market capitalization of $3.51 billion and generates $972.40 million in revenue each year. The company earns $126.50 million in net income (profit) each year or $2.58 on an earnings per share basis. Ingevity employs 1,500 workers across the globe.

Ingevity's mailing address is 5255 VIRGINIA AVENUE, NORTH CHARLESTON SC, 29406. The company can be reached via phone at 843-740-2300 or via email at [email protected]